Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Mayo Clinic Proceedings. Innovations, Quality & Outcomes|November 24, 2021
Computer-Based Patient Bias and Misconduct Training Impact on Reports to Incident Learning SystemCaroline G Wilker, Abigail L Stockham, Benjamin J Houge, et al.
The Journal of Infectious Diseases|November 18, 2021
Monoclonal Antibody Treatment of Breakthrough COVID-19 in Fully Vaccinated Individuals with High-Risk ComorbiditiesDennis M Bierle, Ravindra Ganesh, Sidna Tulledge-Scheitel, et al.
Journal of Primary Care & Community Health|May 25, 2021
Influence of Social and Cultural Factors on the Decision to Consent for Monoclonal Antibody Treatment among High-Risk Patients with Mild-Moderate COVID-19Dennis M Bierle, Ravindra Ganesh, Caroline G Wilker, et al.
Mayo Clinic Proceedings|February 5, 2022
Effectiveness of Monoclonal Antibodies in Preventing Severe COVID-19 With Emergence of the Delta VariantJohn C O'Horo, Douglas W Challener, Leigh Speicher, et al.
Eclinicalmedicine|September 6, 2021
Casirivimab-Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19Raymund R Razonable, Colin Pawlowski, John C O'Horo, et al.
Medrxiv : the Preprint Server for Health Sciences|June 2, 2021
Association of Intravenous Bamlanivimab Use with Reduced Hospitalization, Intensive Care Unit Admission, and Mortality in Patients with Mild to Moderate COVID-19Ravindra Ganesh, Colin Pawlowski, John C O'Horo, et al.
The Journal of Infectious Diseases|July 19, 2021
Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease 2019Ravindra Ganesh, Lindsey M Philpot, Dennis M Bierle, et al.
The Journal of Clinical Investigation|August 19, 2021
Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19Ravindra Ganesh, Colin F Pawlowski, John C O'Horo, et al.
Mayo Clinic Proceedings|May 7, 2021
A Framework for Outpatient Infusion of Antispike Monoclonal Antibodies to High-Risk Patients with Mild-to-Moderate Coronavirus Disease-19: The Mayo Clinic ModelRaymund R Razonable, Nicole C E Aloia, Ryan J Anderson, et al.
Pageof 1